利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

272 条记录 (耗时 0.021 秒)

    Decompression-compensating instrument for ocular surgery, instrument for ocular surgery provided with same and method of ocular surgery
    81.
    发明申请
    Decompression-compensating instrument for ocular surgery, instrument for ocular surgery provided with same and method of ocular surgery 有权
    用于眼部手术的减压补偿仪器，眼外科手术与眼部手术相同，方法

    公开(公告)号：US20060058811A1

    公开(公告)日：2006-03-16

    申请号：US10512867

    申请日：2003-06-20

    申请人： Makoto Kishimoto ,  Yoshiyuki Kimura

    发明人： Makoto Kishimoto ,  Yoshiyuki Kimura

    IPC分类号： A61F9/00

    CPC分类号： A61M1/0058 ,  A61F9/00736 ,  A61M1/0031

    摘要： The present invention relates to a decompression-compensating instrument for use in intraocular surgery, wherein a perfusate is supplied to an affected part of an eye via a supply channel at a predetermined pressure, and the perfusate is aspirated via an aspiration channel together with the affected tissues that are to be removed, the decompression-compensating instrument supplying the perfusate into the affected part when the internal pressure of the affected part is excessively lowered, and being constructed so as to be connectable to a point midway along the supply channel and comprising a storage-member that forms a chamber that is closable except for an opening from which the perfusate to be supplied to the supply channel flows, the capacity of the storage member being 7 cm3 to 22 cm3.

    摘要翻译： 本发明涉及一种用于眼内手术的减压补偿装置，其中，通过供给通道以预定的压力将灌注液供应到眼睛的受影响部位，并且通过吸入通道与受影响的患者一起吸出灌洗液 要被去除的组织，当受影响部分的内部压力过度降低时，减压补偿仪器将灌注液供应到患部，并且构造成可连接到沿着供应通道的中途的点，并且包括 除了供给到供给通道的灌注液的开口以外，形成能够关闭的室的储存部件流动，储存部件的容积为7cm 3〜22cm， 3 。

    Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
    82.
    发明授权
    Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid 失效
    溶解吡啶酮羧酸增溶剂的方法和含有溶解的吡啶酮羧酸的水溶液

    公开(公告)号：US5942508A

    公开(公告)日：1999-08-24

    申请号：US17499

    申请日：1998-02-02

    申请人： Shirou Sawa

    发明人： Shirou Sawa

    IPC分类号： A61K9/00 ,  A61K31/435 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/495 ,  A61K31/496 ,  A61K31/50 ,  A61K31/5025 ,  A61K31/535 ,  A61K31/5383 ,  A61K47/12 ,  A61K31/19 ,  A61K31/445

    CPC分类号： A61K47/12 ,  A61K31/435 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/495 ,  A61K31/496 ,  A61K31/50 ,  A61K31/5025 ,  A61K31/535 ,  A61K31/5383 ,  A61K9/0043 ,  A61K9/0048

    摘要： A method for solubilizing a pyridonecarboxylic acid or a pharmacologically acceptable salt thereof, which comprises adding an arylcarboxylic acid of the formula (I):L.sup.1 --R.sup.1 COOH (I)wherein L.sup.1 is an optionally substituted heterocyclic group or aryl group having not more than 14 carbon atoms, and R.sup.1 is an optionally substituted alkyl group having not more than 4 carbon atoms or a single bond, to the pyridonecarboxylic acid or the pharmacologically acceptable salt thereof, a solubilizer thereof and an aqueous solution containing a solubilized pyridonecarboxylic acid. According to the solubilization method of the present invention, the solubility of pyridonecarboxylic acid compounds and salts thereof at near physiological pH can be increased, thereby making the production of an aqueous solution to be used as an eye drop, nasal drop, ear drop and the like possible.

    摘要翻译： 一种溶解吡啶酮羧酸或其药理学上可接受的盐的方法，其包括加入式（I）的芳基羧酸：其中L 1为任选取代的杂环基或不多于14个碳的芳基的L1-R1COOH（Ⅰ） 原子，R 1为不大于4个碳原子或单键的任选取代的烷基，与吡啶酮羧酸或其药理学上可接受的盐，其增溶剂和含有溶解的吡啶酮羧酸的水溶液。 根据本发明的溶解方法，可以提高吡啶酮羧酸化合物及其盐在接近生理pH下的溶解度，从而使水溶液的制备用作滴眼剂，滴鼻剂，滴耳剂和 像可能的

    Piperazine derivatives and use as cysteine inhibitors
    83.
    发明授权
    Piperazine derivatives and use as cysteine inhibitors 失效
    哌嗪衍生物并用作半胱氨酸抑制剂

    公开(公告)号：US5935959A

    公开(公告)日：1999-08-10

    申请号：US983034

    申请日：1998-01-07

    申请人： Jun Inoue ,  Yuka Yoshida ,  Ying-She Cui ,  Mitsuyoshi Azuma

    发明人： Jun Inoue ,  Yuka Yoshida ,  Ying-She Cui ,  Mitsuyoshi Azuma

    IPC分类号： C07D303/48 ,  A61K31/495 ,  C07D405/06 ,  C07D405/14

    CPC分类号： C07D303/48

    摘要： The present invention is directed to a compound of the following formula (I) inclusive of its salt ##STR1## �wherein R.sup.1 represents either carboxy which may be esterified or amidated carboxy which may be substituted; R.sup.2 represents hydrogen or lower alkyl and may be linked to R.sup.3 or R.sup.4 to form a ring; R.sup.3 and R.sup.4 may be the same or different and each represents hydrogen, lower alkyl which may be substituted, or a sulfide group which may be substituted, and R.sup.3 and R.sup.4 may conjoinedly form a ring; R.sup.5 represents a substituted phenyl group of formula (II) ##STR2## (wherein R.sup.6 represents halogen or alkoxy) or a substituted sulfonyl group of formula (III)--SO.sub.2 --R.sup.7 (III)(wherein R.sup.7 represents either aryl which may be substituted by lower alkyl or amino which may be substituted); n is to 0 or 1! and to a method for producing the same compound, which is useful for the treatment of cysteine protease-associated diseases.

    摘要翻译： PCT No.PCT / JP96 / 01884第 371日期：1998年1月7日 102（e）1998年1月7日PCT PCT 1996年7月4日PCT公布。 公开号WO97 / 03060 PCT 日本1997年1月30日本发明涉及下述式（I）的化合物，其中包括其盐[其中R 1表示可以被酯化或酰胺化的羧基的羧基; R 2表示氢或低级烷基，并且可以与R 3或R 4连接形成环; R 3和R 4可以相同或不同，各自表示氢，可被取代的低级烷基或可被取代的硫基，R3和R4可以结合形成环; R 5表示式（II）的取代苯基（其中R 6表示卤素或烷氧基）或式（III）-SO 2 -R 7（III）的取代磺酰基（其中R 7表示可被低级烷基取代的芳基或 可以被取代的氨基）; n为0或1]以及可用于治疗半胱氨酸蛋白酶相关疾病的相同化合物的制备方法。

    Aqueous suspension of loteprednol etabonate
    84.
    发明授权
    Aqueous suspension of loteprednol etabonate 失效
    水杨酸乙酯的水悬浮液

    公开(公告)号：US5916550A

    公开(公告)日：1999-06-29

    申请号：US035094

    申请日：1998-03-05

    申请人： Katsuhiro Inada ,  Hideo Terayama

    发明人： Katsuhiro Inada ,  Hideo Terayama

    IPC分类号： A61K9/00 ,  A61K31/56 ,  A61K47/18 ,  A61K31/74

    CPC分类号： A61K9/0048 ,  A61K31/56 ,  A61K47/183 ,  A61K9/0043

    摘要： The conventional aqueous suspension of loteprednol etabonate is not easily amenable to production pH control and entails a pH depression on long-term storage, thus irritating the eye or the nasal mucosa on instillation.When a C2-7 aliphatic amino acid is added to an aqueous suspension of loteprednol etabonate for topical ophthalmic use, the suspension does not undergo pH depression even on prolonged storage, with the result that no irritable response is elicited in the eye or nasal mucosa.

    摘要翻译： 百草酚乙酸酯的常规水悬浮液不易于生产pH控制，并且在长期储存时需要pH抑制，因此在滴注时刺激眼睛或鼻粘膜。 当将C2-7脂肪族氨基酸加入到用于局部眼用药物的百吗泼尼酯的水性悬浮液中时，即使长时间保存，悬浮液也不会经历pH抑制，结果在眼睛或鼻粘膜中不引起易怒的反应。

    1,4-benzoxazine-2-acetic acid compound, method for production thereof and use thereof
    88.
    发明授权
    1,4-benzoxazine-2-acetic acid compound, method for production thereof and use thereof 失效
    1,4-苯并恶嗪-2-乙酸化合物，其制备方法和用途

    公开(公告)号：US5635505A

    公开(公告)日：1997-06-03

    申请号：US666326

    申请日：1996-07-03

    申请人： Takahiro Kumonaka ,  Takema Hase ,  Tomoji Aotsuka ,  Toshio Kurihara ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa ,  Fujio Kobayashi

    发明人： Takahiro Kumonaka ,  Takema Hase ,  Tomoji Aotsuka ,  Toshio Kurihara ,  Yoshiyuki Nakamura ,  Tetsuo Matsui ,  Hiromichi Ishikawa ,  Fujio Kobayashi

    IPC分类号： C07D417/06 ,  A61K31/535

    CPC分类号： C07D417/06

    摘要： A 1,4-benzoxazine-2-acetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, a method for production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and an agent for the prevention and/or treatment of the complications of diabetes, which contain the same. The compound (I) of the present invention and pharmaceutically acceptable salts thereof have aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as an agent for the prevention and/or treatment of the complications of diabetes such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis.

    摘要翻译： PCT No.PCT / JP94 / 00005 Sec。 371日期：1996年7月3日 102（e）日期1996年7月3日PCT 1994年1月6日PCT PCT。 出版物WO95 / 18805 日期1995年7月13日具有式（I）的1,4-苯并恶嗪-2-乙酸化合物其中各符号如说明书中所定义，其药学上可接受的盐，其制备方法 ，以及药物组合物，醛糖还原酶抑制剂和用于预防和/或治疗糖尿病并发症的药剂，其含有该组合物。 本发明的化合物（I）及其药学上可接受的盐具有醛糖还原酶抑制作用，安全性优异。 因此，它们可用作预防和/或治疗糖尿病并发症的药剂，例如角膜损伤，白内障，神经症，视网膜病变和肾病，尤其是白内障和神经症。

    Method for preserving blood using ascorbic acid tocopheryl phosphate esters
    90.
    发明授权
    Method for preserving blood using ascorbic acid tocopheryl phosphate esters 失效
    使用抗坏血酸生育磷酸酯保存血液的方法

    公开(公告)号：US5480773A

    公开(公告)日：1996-01-02

    申请号：US301387

    申请日：1994-09-07

    申请人： Kazumi Ogata ,  Kenichi Yoshida

    发明人： Kazumi Ogata ,  Kenichi Yoshida

    IPC分类号： A01N1/02

    CPC分类号： A01N1/0226 ,  A01N1/02

    摘要： A method for the preservation of blood and a blood preserving composition comprising a phosphoric acid diester of the following formula: ##STR1## (wherein R.sub.1 and R.sub.2 are the same or different and each represents a hydrogen atom or a methyl group) or a pharmacologically acceptable salt thereof.The compounds used for the object of the invention are capable of maintaining the biological function of blood for a long period of time without harming its components. Therefore, the composition of the invention can be advantageously used for preserving blood and its components such as erythrocytes, leukocytes and platelets, and is useful for preventing hepatic disorder which can accompany blood transfusion.

    摘要翻译： 一种保存血液的方法和含有下式的磷酸二酯的防血剂组合物：其中R1和R2相同或不同，各自表示氢原子或甲基）或药理学上可接受的 的盐。 用于本发明目的的化合物能够长时间维持血液的生物学功能而不损害其组分。 因此，本发明的组合物可有利地用于保存血液及其成分如红细胞，白细胞和血小板，并且可用于预防伴随输血的肝脏疾病。